The treatment landscape of metastatic kidney cancer - European Medical Journal

Continue

The treatment landscape of metastatic kidney cancer

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, provides an overview of the current unmet needs in the treatment of metastatic kidney cancer.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given